Patents Assigned to Pieris AG
-
Publication number: 20160280747Abstract: The invention relates to the production of novel proteins exhibiting bonding activity for certain ligands, the so-called anticalins. To this end, the structure of peptides of the lipocalin family is modified by amino acid replacement in their natural ligand binding pocket using generic engineering methods. A like immunoglobulin, the anticalin thus obtained can be used to identify or bond molecular structures.Type: ApplicationFiled: April 6, 2016Publication date: September 29, 2016Applicant: Pieris AGInventors: ARNE SKERRA, Gerald Beste, Frank Schmidt, Thomas Stibora
-
Publication number: 20160256525Abstract: The present invention relates to novel muteins derived from human tear lipocalin. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.Type: ApplicationFiled: December 28, 2015Publication date: September 8, 2016Applicant: Pieris AGInventors: Kristian Jensen, Martin Huelsmeyer, Steffen Schlehuber, Andreas Hohlbaum, Arne Skerra, Eric Boudreau, Richard Jones, Ian Kimber, Rebecca Dearman
-
Publication number: 20160200780Abstract: The present invention relates to novel muteins derived from human tear lipocalin having affinity to human c-Met receptor tyrosin kinase (c-Met). The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.Type: ApplicationFiled: December 14, 2015Publication date: July 14, 2016Applicant: PIERIS AGInventors: GABRIELE MATSCHINER, ANDREAS HOHLBAUM, MARTIN HUELSMEYER, STEFAN TRENTMANN
-
Patent number: 9260492Abstract: Described are specific-binding therapeutic and/or diagnostic proteins directed against Glypican-3 (GPC3), which proteins include muteins of a lipocalin protein, such as lipocalin 2 (Lcn2 or NGAL). The invention also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, the invention also is directed to pharmaceutical and/or diagnostic compositions comprising such lipocalin proteins, including uses of these proteins.Type: GrantFiled: November 15, 2011Date of Patent: February 16, 2016Assignee: Pieris AGInventors: Gabriele Matschiner, Andreas Hohlbaum, Kristian Jensen
-
Patent number: 9221887Abstract: The present invention relates to novel muteins derived from human tear lipocalin. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.Type: GrantFiled: September 14, 2012Date of Patent: December 29, 2015Assignee: Pieris AGInventors: Kristian Jensen, Martin Huelsmeyer, Steffen Schlehuber, Andreas Hohlbaum, Arne Skerra, Eric Boudreau, Richard Jones, Ian Kimber, Rebecca Dearman
-
Patent number: 9221885Abstract: The present invention relates to novel, specific-binding therapeutic and/or diagnostic proteins directed against Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) also known as CD152, which proteins preferably are muteins of a lipocalin protein, more preferably of lipocalin 2 (Lcn2 or NGAL). The invention also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, the invention also is directed to pharmaceutical and/or diagnostic compositions comprising such lipocalin proteins, including uses of these proteins.Type: GrantFiled: December 2, 2011Date of Patent: December 29, 2015Assignee: Pieris AGInventors: Gabriele Matschiner, Andreas Hohlbaum, Arne Skerra
-
Publication number: 20150369821Abstract: The present invention relates to lipocalin-mutein assays for measuring hepcidin concentration as well as methods preparing and utilizing and kits leveraging the lipocalin-mutein assays.Type: ApplicationFiled: February 5, 2014Publication date: December 24, 2015Applicant: PIERIS AGInventors: Stefan TRENTMANN, Rachida SIHAM BEL AIBA, Andrea ALLERSDORFER, Nicole ANDERSEN, Andreas HOHLBAUM
-
Patent number: 9212208Abstract: The present invention relates to novel muteins derived from human tear lipocalin having affinity to human c-Met receptor tyrosin kinase (c-Met). The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.Type: GrantFiled: January 29, 2009Date of Patent: December 15, 2015Assignee: Pieris AGInventors: Gabriele Matschiner, Andreas Hohlbaum, Martin Huelsmeyer, Stefan Trentmann
-
Publication number: 20150344538Abstract: The present invention relates to novel, specific-binding therapeutic and/or diagnostic polypeptides directed against the target of Swiss Prot Q16552 and novel, specific-binding therapeutic and/or diagnostic polypeptides directed against the target of Swiss Prot Q9NPF7. In addition, the present invention relates to novel, specific-binding therapeutic and/or diagnostic polypeptides directed against one or both of Swiss Prot Q16552 and Swiss Prot Q9NPF7. The invention also relates to nucleic acid molecules encoding such polypeptides and to methods for generation of such polypeptides and nucleic acid molecules. In addition, the invention is directed to compositions comprising the polypeptides, and therapeutic and/or diagnostic uses of these polypeptides.Type: ApplicationFiled: November 20, 2013Publication date: December 3, 2015Applicant: PIERIS AGInventors: Marlon HINNER, Laurent AUDOLY, Martin HUELSMEYER, Kristian JENSEN, Gabriele MATSCHINER, Shane OLWILL, Alexander WIEDENMANN, Andrea ALLERSDORFER
-
Publication number: 20150291675Abstract: The present invention relates to novel, specific-binding therapeutic and/or diagnostic proteins directed against Hepcidin, which proteins preferably are muteins of lipocalin protein. The invention also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, the invention also is directed to pharmaceutical and/or diagnostic compositions comprising such a lipocalin proteins, including uses of these proteins.Type: ApplicationFiled: May 6, 2015Publication date: October 15, 2015Applicant: PIERIS AGInventors: STEFAN TRENTMANN, GABRIELE MATSCHINER, ARNE SKERRA, ANDREAS HOHLBAUM, MARTIN HUELSMEYER, HENDRIK GILLE, HANS-JUERGEN CHRISTIAN, KRISTIAN JENSEN, RACHIDA SIHAM BEL AIBA
-
Publication number: 20150284435Abstract: The present invention relates to novel, specific-binding therapeutic and/or diagnostic lipocalin muteins directed against Glypican-3 (GPC-3). The invention also relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the invention also is directed to pharmaceutical compositions comprising such muteins and practical uses of these lipocalin muteins. In addition, the present invention provides methods of using muteins of human lipocalin 2 (Lcn2 or NGAL) for target-specific delivery of therapeutic moieties or detectable labels to cells expressing GPC-3, and related therapeutic and diagnostic utilization.Type: ApplicationFiled: May 21, 2013Publication date: October 8, 2015Applicant: PIERIS AGInventor: Klaus Kirchfield
-
Publication number: 20150283207Abstract: The present invention relates to novel muteins derived from human tear lipocalin, which bind to IL 4 receptor alpha. The sequences of the muteins comprise particular combinations of amino acids. In particular a mutated amino acid residue is present at any one or more of the sequence positions 27, 28, 30, 31, 33, 53, 57, 61, 64, 66, 80, 83, 104-106 and 108 of the linear polypeptide sequence of the mature human tear lipocalin. A mutated amino acid residue is also present at any 2 or more of the sequence positions 26, 32, 34, 55, 56, 58 and 63 of the linear polypeptide sequence of the mature human tear lipocalin. The invention also provides a corresponding nucleic acid molecule encoding such a mutein and a method for producing such a mutein and its encoding nucleic acid molecule.Type: ApplicationFiled: March 23, 2015Publication date: October 8, 2015Applicant: PIERIS AGInventors: Andreas HOHLBAUM, Alexandra Baehre, Gabriele Matschiner, Stefan Trentmann, Klaus Kirchfield, Hans-Juergen Christian
-
Patent number: 9051382Abstract: The present invention relates to novel, specific-binding therapeutic and/or diagnostic proteins directed against Hepcidin, which proteins preferably are muteins of a lipocalin protein. The invention also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, the invention also is directed to pharmaceutical and/or diagnostic compositions comprising such a lipocalin proteins, including uses of these proteins.Type: GrantFiled: August 16, 2011Date of Patent: June 9, 2015Assignee: PIERIS AGInventors: Stefan Trentmann, Gabriele Matschiner, Arne Skerra, Andreas Hohlbaum, Martin Huelsmeyer, Hendrik Gille, Hans-Juergen Christian, Kristian Jensen, Rachida Siham Bel Aiba
-
Patent number: 8986951Abstract: The present invention relates to novel muteins derived from human tear lipocalin, which bind to IL 4 receptor alpha. The sequences of the muteins comprise particular combinations of amino acids. In particular a mutated amino acid residue is present at any one or more of the sequence positions 27, 28, 30, 31, 33, 53, 57, 61, 64, 66, 80, 83, 104-106 and 108 of the linear polypeptide sequence of the mature human tear lipocalin. A mutated amino acid residue is also present at any 2 or more of the sequence positions 26, 32, 34, 55, 56, 58 and 63 of the linear polypeptide sequence of the mature human tear lipocalin. The invention also provides a corresponding nucleic acid molecule encoding such a mutein and a method for producing such a mutein and its encoding nucleic acid molecule.Type: GrantFiled: June 8, 2011Date of Patent: March 24, 2015Assignee: Pieris AGInventors: Andreas Hohlbaum, Alexandra Baehre, Gabriele Matschiner, Stefan Trentmann, Klaus Kirchfeld, Hans-Juergen Christian
-
Publication number: 20140288008Abstract: The present disclosure relates to novel lipocalin muteins which bind to PCSK9. The disclosure also provides corresponding nucleic acid molecules encoding lipocalin muteins and methods for producing lipocalin muteins as well as their encoding nucleic acid molecules.Type: ApplicationFiled: March 13, 2014Publication date: September 25, 2014Applicants: Daiichi Sankyo Company, Limited, Pieris AGInventors: GABRIELE MATSCHINER, CHRISTINE ROTHE, ANDREAS HOHLBAUM, ANDREA ALLERSDORFER, RACHIDA SIHAM BEL AIBA, MARLON HINNER, ALEXANDER WIEDENMANN, SHINJI YAMAGUCHI, TAKAHIDE ABURATANI, RYUJI HASHIMOTO, TOHRU TAKAHASHI, CHIKAKO NAGASAKI, FUTOSHI NARA, TOMOHIRO NISHIZAWA
-
Publication number: 20140080177Abstract: The invention relates to the production of novel proteins exhibiting bonding activity for certain ligands, the so-called anticalins. To this end, the structure of peptides of the lipocalin family is modified by amino acid replacement in their natural ligand binding pocket using generic engineering methods. Alike immunoglobulin, the anticalin thus obtained can be used to identify or bond molecular structures.Type: ApplicationFiled: August 20, 2013Publication date: March 20, 2014Applicant: Pieris AGInventors: Arne Skerra, Gerald Beste, Frank Schmidt, Thomas Stibora
-
Patent number: 8536307Abstract: The invention relates to the production of novel proteins exhibiting binding activity for certain ligands, the so-called anticalins. To this end, the structure of peptides of the lipocalin family is modified by amino acid replacement in their natural ligand binding pocket using genetic engineering methods. Like immunoglobulin, the anticalin thus obtained can be used to identify or bind molecular structures.Type: GrantFiled: March 19, 2012Date of Patent: September 17, 2013Assignee: Pieris AGInventors: Arne Skerra, Gerald Beste, Frank Schmidt, Thomas Stibora
-
Patent number: 8313924Abstract: The present invention relates to novel muteins derived from human tear lipocalin. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.Type: GrantFiled: August 1, 2007Date of Patent: November 20, 2012Assignee: Pieris AGInventors: Kristian Jensen, Martin Huelsmeyer, Steffen Schlehuber, Andreas Hohlbaum, Arne Skerra, Eric Boudreau, Richard Jones, Ian Kimber, Rebecca Dearman
-
Publication number: 20120201873Abstract: The present invention relates to pharmaceutical compositions for the controlled release of lipocalin muteins and conjugates thereof with a moiety selected from the group consisting of a protein, protein domain, peptide, lipid, fatty acid, polysaccharide and/or an organic polymer that comprise said lipocalin mutein of conjugate thereof in combination with a biodegradable polymer. The invention further relates to a method for the controlled delivery of the lipocalin muteins or conjugates thereof, methods for the production of a controlled release formulation and the thus produced formulation.Type: ApplicationFiled: August 5, 2010Publication date: August 9, 2012Applicant: PIERIS AGInventors: Andreas Hohlbaum, Martin Huelsmeyer, Hendrik Gille, Sankaram Bhima Mantripragada, Kathleen Marie Campbell
-
Patent number: 8158753Abstract: The invention relates to the production of novel proteins exhibiting bonding activity for certain ligands, the so-called anticalins. To this end, the structure of peptides of the lipocalin family is modified by amino acid replacement in their natural ligand binding pocket using generic engineering methods. Alike immunoglobulin, the anticalin thus obtained can be used to identify or bond molecular structures.Type: GrantFiled: January 5, 2010Date of Patent: April 17, 2012Assignee: Pieris AGInventors: Arne Skerra, Gerald Beste, Frank Schmidt, Thomas Stibora